12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Company News  |  Deals

Covagen, Mitsubishi Tanabe Pharma deal

Covagen will use its Fynomer protein engineering technology to develop bispecific proteins against two undisclosed target pairs from Mitsubishi Tanabe. For the first target pair, Mitsubishi will pay Covagen €4 million ($5.2 million) up...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >